We are live on ! Find out more
VYNT

Vyant Bio

Delisted

VYNT was delisted on the 12th of May, 2023.

32 hedge funds and large institutions have $10.4M invested in Vyant Bio in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more capital inflows, than outflows

Capital inflows: $1.38M | Capital outflows: $445K

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

10% more funds holding

Funds holding: 29 → 32 (+3)

1.68% more ownership

Funds ownership: 11.7% → 13.37% (+1.7%)

Holders
32
Holders Change
+3
Holders Change %
+10.34%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
8
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VYNT Hedge Fund Activity: Q1 2017 in Review

32 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio (VYNT) for Q1 2017, worth a combined $10.4M — up 248% from $2.98M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new VYNT positions and 7 closed out — a net gain of 4 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $330K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $181K.

  • 32 institutional investors held Vyant Bio (VYNT) as of Q1 2017, up from 29 in Q4 2016.
  • Funds reported $10.4M of Vyant Bio stock for Q1 2017, up 248% quarter-over-quarter.
  • 11 funds opened new Vyant Bio positions in Q1 2017 and 7 closed out, a net change of +4 holders.
  • The largest Vyant Bio buyer in Q1 2017 was Renaissance Technologies, an estimated $330K added.
  • The largest Vyant Bio seller in Q1 2017 was Jacobs Levy Equity Management, an estimated $181K sold.

Based on aggregated 13F filings for Q1 2017.